In mono vaccine, EVM is a member of the herpes virus family and one of the most common viruses in humans, with nearly all adults in developed countries such as the United States having been inflected. EBV is often asymptomatic but commonly causes infectious mononucleosis, with 30 to 40 percent of adolescents who contract the virus developing the disease.
EBV is also associated with a number of other diseases, some of the most serious being compromised immune systems. Such as transplant patients. Despite the frequency of EBV infections and infectious mononucleosis, the new study is the first to suggest the efficacy of a vaccine in preventing infectious mononucleosis.
The vaccine targets glycoprotein 350, a protein that facilitates the entry EBV into immune system cells. In this preliminary, clinical trial.181 young adults who had not previously been infected by EBV received three doses of either a placebo or the vaccine. During the 18 month observation period the proportion of symptomatic EBV infections was reduced from 10 percent in the control group to 2 percent in the vaccinated group.
Doctor suggested the next step should be “large-scale studies on the benefit in healthy subjects and ability to prevent acute EBV infection and post-transplant lymph proliferative diseases in transplant patients.” He added, “There is currently no possibility to prevent or to treat acute mononucleosis, which has remained so far an unmet medical problem. This vaccine may decrease the socio-economic impact of acute mononucleosis.”
These results suggest that prevention of infectious mononucleosis is possible, and provide a framework for future trials looking to prevent more serious consequences of EBV infection.